Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

belvarafenib (RG6185)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Hanmi

Drug class:

pan-RAF inhibitor

Related drugs:

NRAS mutation	Melanoma	NRAS mutation	Melanoma	RG6185 Resistant: C3 – Early Trials RG6185 Resistant : C3	RG6185 Resistant: C3 – Early Trials RG6185 Resistant : C3
NRAS mutation	Melanoma	NRAS mutation	Melanoma	cobimetinib + RG6185 Sensitive: C3 – Early Trials cobimetinib + RG6185 Sensitive : C3	cobimetinib + RG6185 Sensitive: C3 – Early Trials cobimetinib + RG6185 Sensitive : C3
HRAS mutation	Melanoma	HRAS mutation	Melanoma	cobimetinib + RG6185 Sensitive: C3 – Early Trials cobimetinib + RG6185 Sensitive : C3	cobimetinib + RG6185 Sensitive: C3 – Early Trials cobimetinib + RG6185 Sensitive : C3
KRAS G13	Colorectal Cancer	KRAS G13	Colorectal Cancer	cobimetinib + RG6185 Sensitive: C3 – Early Trials cobimetinib + RG6185 Sensitive : C3	cobimetinib + RG6185 Sensitive: C3 – Early Trials cobimetinib + RG6185 Sensitive : C3
BRAF mutation	Non Small Cell Lung Cancer	BRAF mutation	Non Small Cell Lung Cancer	cobimetinib + RG6185 Sensitive: C3 – Early Trials cobimetinib + RG6185 Sensitive : C3	cobimetinib + RG6185 Sensitive: C3 – Early Trials cobimetinib + RG6185 Sensitive : C3
BRAF mutation	Melanoma	BRAF mutation	Melanoma	cobimetinib + RG6185 Sensitive: C3 – Early Trials cobimetinib + RG6185 Sensitive : C3	cobimetinib + RG6185 Sensitive: C3 – Early Trials cobimetinib + RG6185 Sensitive : C3
BRAF V600	Melanoma	BRAF V600	Melanoma	cobimetinib + RG6185 Sensitive: C3 – Early Trials cobimetinib + RG6185 Sensitive : C3	cobimetinib + RG6185 Sensitive: C3 – Early Trials cobimetinib + RG6185 Sensitive : C3
BRAF fusion	Solid Tumor	BRAF fusion	Solid Tumor	cobimetinib + RG6185 Sensitive: C3 – Early Trials cobimetinib + RG6185 Sensitive : C3	cobimetinib + RG6185 Sensitive: C3 – Early Trials cobimetinib + RG6185 Sensitive : C3
BRAF mutation	Thyroid Gland Carcinoma	BRAF mutation	Thyroid Gland Carcinoma	RG6185 Sensitive: D – Preclinical RG6185 Sensitive : D	RG6185 Sensitive: D – Preclinical RG6185 Sensitive : D
KRAS mutation	Thyroid Gland Carcinoma	KRAS mutation	Thyroid Gland Carcinoma	RG6185 Sensitive: D – Preclinical RG6185 Sensitive : D	RG6185 Sensitive: D – Preclinical RG6185 Sensitive : D
NRAS G13D	Melanoma	NRAS G13D	Melanoma	atezolizumab + RG6185 Sensitive: D – Preclinical atezolizumab + RG6185 Sensitive : D	atezolizumab + RG6185 Sensitive: D – Preclinical atezolizumab + RG6185 Sensitive : D
BRAF V600E	Melanoma	BRAF V600E	Melanoma	RG6185 Sensitive: D – Preclinical RG6185 Sensitive : D	RG6185 Sensitive: D – Preclinical RG6185 Sensitive : D
ARAF mutation + NRAS mutation	Melanoma	ARAF mutation + NRAS mutation	Melanoma	RG6185 Resistant: D – Preclinical RG6185 Resistant : D	RG6185 Resistant: D – Preclinical RG6185 Resistant : D
NRAS mutation	Melanoma	NRAS mutation	Melanoma	atezolizumab + RG6185 Sensitive: D – Preclinical atezolizumab + RG6185 Sensitive : D	atezolizumab + RG6185 Sensitive: D – Preclinical atezolizumab + RG6185 Sensitive : D
NRAS mutation	Acute Myelogenous Leukemia	NRAS mutation	Acute Myelogenous Leukemia	cobimetinib + RG6185 Sensitive: D – Preclinical cobimetinib + RG6185 Sensitive : D	cobimetinib + RG6185 Sensitive: D – Preclinical cobimetinib + RG6185 Sensitive : D
KRAS mutation	Acute Myelogenous Leukemia	KRAS mutation	Acute Myelogenous Leukemia	cobimetinib + RG6185 Sensitive: D – Preclinical cobimetinib + RG6185 Sensitive : D	cobimetinib + RG6185 Sensitive: D – Preclinical cobimetinib + RG6185 Sensitive : D
NRAS mutation	Acute Myelogenous Leukemia	NRAS mutation	Acute Myelogenous Leukemia	RG6185 Sensitive: D – Preclinical RG6185 Sensitive : D	RG6185 Sensitive: D – Preclinical RG6185 Sensitive : D
KRAS mutation	Acute Myelogenous Leukemia	KRAS mutation	Acute Myelogenous Leukemia	RG6185 Sensitive: D – Preclinical RG6185 Sensitive : D	RG6185 Sensitive: D – Preclinical RG6185 Sensitive : D
ZMYM2-FGFR1 fusion	Leukemia	ZMYM2-FGFR1 fusion	Leukemia	RG6185 Sensitive: D – Preclinical RG6185 Sensitive : D	RG6185 Sensitive: D – Preclinical RG6185 Sensitive : D